October 2017
VBI Vaccines Inc.
Canaccord Genuity acts as Joint Bookrunning Manager for US$49.1 million follow-on offering
Canaccord Genuity is pleased to announce that on October 31, 2017, VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced the closing of its underwritten public offering of 16,100,000 common shares, which included 2,100,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares at a price to the public of US$3.05 per share.
VBI’s previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million. All shares offered in both the underwritten public offering and the registered direct offering were offered at a price of US$3.05 per share. The expected aggregate gross proceeds to VBI from the offerings are US$71.9 million, before deducting the underwriting discounts and commissions and estimated offering expenses.
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.